Patents by Inventor Kenneth H. Roux

Kenneth H. Roux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Purified linear epitopes from cashew nuts, nucleic acids encoding therefor and associated methods
    Patent number: 8273856
    Abstract: Disclosed are major allergenic proteins in cashew nut, which are legumin-like proteins and 2S albumins. Also disclosed is a polypeptide allergen in the 7S superfamily, which includes vicilin-like and sucrose binding proteins. Several linear epitopes of the cashew nut are identified and characterized. The invention further discloses the sequence of cDNA encoding the allergenic polypeptide, the allergen being designated Ana o 1, and also describes the characterization of the expressed recombinant polypeptide and associated methods employing the polypeptide.
    Type: Grant
    Filed: May 15, 2009
    Date of Patent: September 25, 2012
    Assignee: Florida State University Research Foundation, Inc.
    Inventors: Kenneth H. Roux, Shridhar K. Sathe, Suzanne S. Teuber
  • Diagnostic test for detecting anti-cashew IgE in patients
    Patent number: 8114605
    Abstract: Disclosed are major allergenic proteins in cashew nut, which are legumin-like proteins and 2S albumins. Also disclosed is a polypeptide allergen in the 7S superfamily, which includes vicilin-like and sucrose binding proteins. Several linear epitopes of the cashew nut are identified and characterized. The invention further discloses the sequence of cDNA encoding the allergenic polypeptide, the allergen being designated Ana o 1, and also describes the characterization of the expressed recombinant polypeptide and associated methods employing the polypeptide.
    Type: Grant
    Filed: February 5, 2008
    Date of Patent: February 14, 2012
    Assignee: Florida State University Research Foundation, Inc.
    Inventors: Kenneth H. Roux, Shridhar K. Sathe, Suzanne S. Teuber
  • Purified linear polypeptide epitopes from walnuts and associated methods
    Patent number: 8007770
    Abstract: A purified Ig-E binding immunogenic polypeptide the amino acid sequence of which consists of SEQ ID NO:1 is disclosed. The purified amino acid sequence is a major allergen of the walnut Juglans regia. Also described are a diagnostic test kit and use of the purified polypeptide in tests for identifying patients having an allergy to walnuts. Mutations of the disclosed polypeptide, as well as nucleic acid sequences encoding therefor are claimed as part of the invention.
    Type: Grant
    Filed: July 23, 2010
    Date of Patent: August 30, 2011
    Assignee: The Florida State University Research Foundation, Inc.
    Inventors: Kenneth H. Roux, Shridhar K. Sathe, Jason M. Robotham, Suzanne S. Teuber
  • Purified Linear Epitopes From Cashew Nuts, Nucleic Acids Endcoding Therefor And Associated Methods
    Publication number: 20100311603
    Abstract: Disclosed are major allergenic proteins in cashew nut, which are legumin-like proteins and 2S albumins. Also disclosed is a polypeptide allergen in the 7S superfamily, which includes vicilin-like and sucrose binding proteins. Several linear epitopes of the cashew nut are identified and characterized. The invention further discloses the sequence of cDNA encoding the allergenic polypeptide, the allergen being designated Ana o 1, and also describes the characterization of the expressed recombinant polypeptide and associated methods employing the polypeptide.
    Type: Application
    Filed: May 15, 2009
    Publication date: December 9, 2010
    Inventors: Kenneth H. Roux, Shridhar K. Sathe, Suzanne S. Teuber
  • Purified linear epitopes from cashew nuts, nucleic acids encoding therefor, and associated methods
    Patent number: 7538203
    Abstract: Disclosed are major allergenic proteins in cashew nut, which are legumin-like proteins and 2S albumins. Also disclosed is a polypeptide allergen in the 7S superfamily, which includes vicilin-like and sucrose binding proteins. Several linear epitopes of the cashew nut are identified and characterized. The invention further discloses the sequence of cDNA encoding the allergenic polypeptide, the allergen being designated Ana o 1, and also describes the characterization of the expressed recombinant polypeptide and associated methods employing the polypeptide.
    Type: Grant
    Filed: April 1, 2005
    Date of Patent: May 26, 2009
    Assignee: Florida State University Research Foundation, Inc.
    Inventors: Kenneth H. Roux, Shridhar K. Sathe, Suzanne S. Teuber
  • Purified linear epitopes from cashew nuts, nucleic acids encoding therefor, and associated methods
    Patent number: 7381534
    Abstract: Disclosed are major allergenic proteins in cashew nut, which are legumin-like proteins and 2S albumins. Also disclosed is a polypeptide allergen in the 7S superfamily, which includes vicilin-like and sucrose binding proteins. Several linear epitopes of the cashew nut are identified and characterized. The invention further discloses the sequence of cDNA encoding the allergenic polypeptide, the allergen being designated Ana o 1, and also describes the characterization of the expressed recombinant polypeptide and associated methods employing the polypeptide.
    Type: Grant
    Filed: April 1, 2005
    Date of Patent: June 3, 2008
    Assignee: Florida State University Research Foundation, Inc.
    Inventors: Kenneth H. Roux, Shridhar K. Sathe, Suzanne S. Teuber
  • Purified linear polypeptide epitope from walnuts and associated methods
    Patent number: 7250489
    Abstract: A purified Ig-E binding immunogenic polypeptide the amino acid sequence of which consists of SEQ ID NO:1 is disclosed. The purified amino acid sequence is a major allergen of the walnut Juglans regia. Also described are a diagnostic test kit and use of the purified polypeptide in tests for identifying patients having an allergy to walnuts. Mutations of the disclosed polypeptide, as well as nucleic acid sequences encoding therefor are claimed as part of the invention.
    Type: Grant
    Filed: September 20, 2002
    Date of Patent: July 31, 2007
    Inventors: Kenneth H. Roux, Shridhar K. Sathe, Jason M. Robotham, Suzanne S. Teuber
  • Compound for treatment of allergy and asthma
    Patent number: 6986889
    Abstract: The present invention relates to a novel drug candidate having a potential for universal therapy of allergy and asthma. The invention provides a Fab (antibody fragment), having the following characteristics: a) inhibits the IgE-Fc?RI interaction; b) binds to free and cell-bound IgE; and c) is non-anaphylactic.
    Type: Grant
    Filed: March 28, 2002
    Date of Patent: January 17, 2006
    Assignee: Pharmacia Diagnostics AB
    Inventors: Sylvia Laffer, Erik Högbom, Kenneth H. Roux, Jonas Adriansson, Wolfgang R. Sperr, Peter Valent, Dietrich Kraft, Hans Grönlund, Rudolf Valenta
  • Purified linear epitopes from cashew nuts, nucleic acids encoding therefor, and associated methods
    Patent number: 6884877
    Abstract: Disclosed are major allergenic proteins in cashew nut, which are legumin-like proteins and 2S albumins. Also disclosed is a polypeptide allergen in the 7S superfamily, which includes vicilin-like and sucrose binding proteins. Several linear epitopes of the cashew nut are identified and characterized. The invention further discloses the sequence of cDNA encoding the allergenic polypeptide, the allergen being designated Ana o 1, and also describes the characterization of the expressed recombinant polypeptide and associated methods employing the polypeptide.
    Type: Grant
    Filed: October 3, 2002
    Date of Patent: April 26, 2005
    Assignee: Florida State University Research Foundation, Inc.
    Inventors: Kenneth H. Roux, Shridhar K. Sathe, Suzanne S. Teuber
  • Purified linear epitopes from cashew nuts, nucleic acids encoding therefor, and associated methods
    Publication number: 20030124060
    Abstract: Disclosed are major allergenic proteins in cashew nut, which are legumin-like proteins and 2S albumins. Also disclosed is a polypeptide allergen in the 7S superfamily, which includes vicilin-like and sucrose binding proteins. Several linear epitopes of the cashew nut are identified and characterized. The invention further discloses the sequence of cDNA encoding the allergenic polypeptide, the allergen being designated Ana o 1, and also describes the characterization of the expressed recombinant polypeptide and associated methods employing the polypeptide.
    Type: Application
    Filed: October 3, 2002
    Publication date: July 3, 2003
    Inventors: Kenneth H. Roux, Shridhar K. Sathe, Suzanne S. Teuber
  • Purified linear polypeptide epitope from walnuts and associated methods
    Publication number: 20030103903
    Abstract: A purified Ig-E binding immunogenic polypeptide the amino acid sequence of which consists of SEQ ID NO:1 is disclosed. The purified amino acid sequence is a major allergen of the walnut Juglans regia. Also described are a diagnostic test kit and use of the purified polypeptide in tests for identifying patients having an allergy to walnuts. Mutations of the disclosed polypeptide, as well as nucleic acid sequences encoding therefor are claimed as part of the invention.
    Type: Application
    Filed: September 20, 2002
    Publication date: June 5, 2003
    Inventors: Kenneth H. Roux, Shridhar K. Sathe, Jason M. Robotham, Suzanne Teuber
  • Novel compound for treatment of allergy and asthma
    Publication number: 20030035796
    Abstract: The present invention relates to a novel drug candidate having a potential for universal therapy of allergy and asthma.
    Type: Application
    Filed: March 28, 2002
    Publication date: February 20, 2003
    Applicant: Pharmacia Deagnostics AB
    Inventors: Sylvia Laffer, Erik Hogbom, Kenneth H. Roux, Jonas Adriansson, Wolfgang R. Sperr, Peter Valent, Dietrich Kraft, Hans Gronlund, Rudolf Valenta
  • Compound for treatment of allergy and asthma
    Patent number: RE42324
    Abstract: The present invention relates to a novel drug candidate having a potential for universal therapy of allergy and asthma. The invention provides a Fab (antibody fragment), having the following characteristics: a) inhibits the IgE-Fc?RI interaction; b) binds to free and cell-bound IgE; and c) is non-anaphylactic.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: May 3, 2011
    Assignee: Phadia AB
    Inventors: Sylvia Laffer, Erik Hogbom, Kenneth H. Roux, Jonas Adriansson, Wolfgang R. Sperr, Peter Valent, Dietrich Kraft, Hans Grönlund, Rudolf Valenta